(PRWEB UK) 26 January 2013
The new report Global Pharmaceutical & Biotechnology Outlook 2013 states that over the next five years, we will witness a surge in approval of new drugs that would deliver a major improvement in the standard of care. Therapy areas - Oncology, Diabetes, Ophthalmology HCV, Atrial Fibrillation, Multiple Sclerosis, Dyslipidemia, Alzheimer's and Melanoma are few select areas where newer therapies that are safer and more efficacious will reach the market.
Many of these innovations promise a paradigm shift in the standard of care. 2012 marked the beginning of this trend as many new blockbuster drug were approved and we also witnessed promising proof of concept data on many of the potential path breaking innovation. There are also major outcome clinical trials that will deliver data over the next few years and if positive, we will see the change in fortunes of many existing drugs that are on the market. View the Report
About Report Buyer.
ReportBuyer.com is the independent online store for global business information. The website now lists more than 300,000 company overviews, market research reports, industry studies and business books from over 300 specialist publishers.